Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic, Madeleine; Pinter-Brown, Lauren C; Foss, Francine M; Sokol, Lubomir; Jorgensen, Jeffrey L; Challagundla, Pramoda; Dwyer, Karen M; Zhang, Xiaoping; Kurman, Michael R; Ballerini, Rocco; Liu, Li; Kim, Youn H.
; 125(12): 1883-9, 2015 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-25605368
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.
Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
Diagnostik kutaner Lymphome.
Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Monoclonal antibodies against cutaneous T-cell lymphomas.
Kutane Lymphome : Klinik Diagnostik Therapie.